Dr. Washington Loses DEA Privileges After State License Revocation
Published Date: 7/8/2025
Notice
Summary
Dr. William Washington lost his medical license in Washington state, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final and immediate. This means Dr. Washington can no longer legally prescribe or manage controlled drugs, effective right now.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Washington
The DEA revoked William Washington, M.D.'s Certificate of Registration No. FW5625213, so he can no longer legally prescribe, dispense, or handle controlled substances. The Washington medical license was permanently revoked on November 26, 2024, an Order to Show Cause was served January 22, 2025, and the DEA Order revoking the DEA registration is effective August 7, 2025.
Pending DEA Applications Denied
The DEA denied any pending applications of William Washington, M.D., to renew or modify Certificate of Registration No. FW5625213 and denied any other pending application for additional registration in Washington. That denial is part of the Order effective August 7, 2025.
Fifteen-Day Reconsideration Right
The registrant may file a properly supported motion for reconsideration of the factual finding that he is not licensed to practice medicine in Washington within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator at [email protected].
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-12607 — Bayer CropScience: Availability of a Petition for a Determination of Nonregulated Status and Draft Plant Pest Risk Assessment for MON 95275 Maize (Corn)
Bayer CropScience wants permission to grow a new type of corn called MON 95275 that protects itself from pesky corn rootworms using special proteins. The government is sharing the petition and a safety check for everyone to review and comment on. Farmers, consumers, and anyone interested can weigh in before a final decision is made, which could change how corn is grown and protected.
Next: 2025-12609 — Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.